Validation of a novel modified aptamer-based array proteomic platform in patients with end-stage renal disease

Zhongji Han, Zhousheng Xiao, Kamyar Kalantar-Zadeh, Hamid Moradi, Tariq Shafi, Sushrut S. Waikar, L. Darryl Quarles, Zhi Yu, Adrienne Tin, Josef Coresh, Csaba P. Kovesdy

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


End stage renal disease (ESRD) is characterized by complex metabolic abnormalities, yet the clinical relevance of specific biomarkers remains unclear. The development of multiplex diagnostic platforms is creating opportunities to develop novel diagnostic and therapeutic approaches. SOMAscan is an innovative multiplex proteomic platform which can measure >1300 proteins. In the present study, we performed SOMAscan analysis of plasma samples and validated the measurements by comparison with selected biomarkers. We compared concentrations of SOMAscan-measured prostate specific antigen (PSA) between males and females, and validated SOMAscan concentrations of fibroblast growth factor 23 (FGF23), FGF receptor 1 (FGFR1), and FGFR4 using Enzyme-Linked immunosorbent assay (ELISA). The median (25th and 75th percentile) SOMAscan PSA level in males and females was 4304.7 (1815.4 to 7259.5) and 547.8 (521.8 to 993.4) relative fluorescence units (p = 0.002), respectively, suggesting biological plausibility. Pearson correlation between SOMAscan and ELISA was high for FGF23 (R = 0.95, p < 0.001) and FGFR4 (R = 0.69, p < 0.001), indicating significant positive correlation, while a weak correlation was found for FGFR1 (R = 0.13, p = 0.16). In conclusion, there is a good to near-perfect correlation between SOMAscan and standard immunoassays for FGF23 and FGFR4, but not for FGFR1. This technology may be useful to simultaneously measure a large number of plasma proteins in ESRD, and identify clinically important prognostic markers to predict outcomes.

Original languageEnglish (US)
Article number71
Issue number4
StatePublished - Dec 1 2018


  • Biomarker
  • End-stage renal disease
  • SOMAscan
  • Validation

ASJC Scopus subject areas

  • Clinical Biochemistry


Dive into the research topics of 'Validation of a novel modified aptamer-based array proteomic platform in patients with end-stage renal disease'. Together they form a unique fingerprint.

Cite this